Related Experiment Video
Updated: Mar 15, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Have adjuvant tyrosine kinase inhibitors lost their shine?
Joshua K Sabari1, Jamie E Chaft2
1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA ;
Abstract:
Despite broad advances in molecularly targeted therapies, lung cancer remains the leading cause of cancer related mortality in the United States. Epidermal growth factor receptor (EGFR) mutations occur in approximately 17% of advanced non-small cell lung cancer (NSCLC) in the US population. The remarkable efficacy of small-molecule EGFR tyrosine kinase inhibitors (TKIs) in this unique subset of patients has revolutionized the therapeutic approach to lung cancer. The success of these agents in the metastatic setting leads to the logical question of what role these drugs may have in the adjuvant setting for patients with earlier stage disease. RADIANT, an international randomized, double-blind, placebo controlled phase III study in patients with completely resected stage IB to IIIA NSLC whose tumors expressed EGFR by IHC and EGFR amplification by FISH, attempted to answer the question of whether erlotinib would improve disease free survival and overall survival in the adjuvant setting. While RADIANT does not conclude for or against adjuvant use of EGFR-TKIs, all data points towards benefit in a selected population. As clinicians, we must continue to enroll to potentially practice changing therapeutic neoadjuvant and adjuvant chemotherapy studies internationally.
Insights
The RADIANT study investigated erlotinib for early-stage non-small cell lung cancer (NSCLC) after surgery. While not definitive, findings suggest potential benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in specific patient groups.
Area of Science:
- Oncology
- Translational Research
Background:
- Lung cancer is a leading cause of cancer mortality despite targeted therapies.
- Epidermal growth factor receptor (EGFR) mutations are present in about 17% of advanced non-small cell lung cancer (NSCLC) cases in the US.
- EGFR tyrosine kinase inhibitors (TKIs) have shown significant efficacy in metastatic NSCLC.
Discussion:
- The RADIANT study evaluated erlotinib's role in the adjuvant setting for resected stage IB-IIIA NSCLC.
- The study assessed if erlotinib improves disease-free survival and overall survival in patients with EGFR expression and amplification.
- While results are inconclusive, trends suggest a potential benefit in a selected patient population.
Key Insights:
- The study did not definitively prove or disprove the adjuvant use of EGFR-TKIs.
- Data indicates a possible survival benefit for erlotinib in a specific subgroup of NSCLC patients.
- Further research and enrollment in clinical trials are crucial.
Outlook:
- Continued enrollment in neoadjuvant and adjuvant chemotherapy trials is essential for advancing NSCLC treatment.
- Identifying specific patient populations who benefit from EGFR-TKIs in the adjuvant setting remains a key research area.
- The findings underscore the importance of personalized medicine in lung cancer therapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...